The thymus defect changes adaptive immunity primarily by impairing T-cell development. This reduced rejection creates a permissive setting for implanted human or mouse tumor cells to establish and grow. Importantly, nude mice retain other immune and physiological systems, so tumor behavior is examined in a living organism rather than in a host with completely absent immune function.
Compared with studies in mice with intact immune systems, nude mouse model experiments place less emphasis on T-cell-mediated rejection and more on tumor growth, invasion, metastasis, or treatment response under reduced adaptive immune pressure. This distinction matters when interpreting results because a therapy that performs well in this setting may not produce the same outcome when patient immune function contributes to tumor control.
Nude mouse models can receive either human or mouse tumor cells, depending on the experimental design. That flexibility supports controlled investigation of tumor behavior across different implanted-tumor settings while preserving the same general host context. In cancer research, it enables researchers to evaluate growth, invasion, metastasis, or treatment responses using tumor material relevant to the specific research question.
A basic study involves implanting human or mouse tumor cells into the nude mice and then examining the resulting tumor behavior under controlled biological conditions. Researchers may focus on growth, invasion, or metastasis, or administer an anticancer drug or radiation to evaluate response. The workflow therefore connects tumor establishment with a defined disease or treatment question.
Measurements of tumor growth can be considered alongside invasion and metastasis to characterize how a cancer develops in vivo. These outcomes provide complementary information rather than a single measure of tumor burden: growth reflects expansion, while invasion and metastasis address broader behavior. Together, they help researchers assess disease progression and compare responses to experimental interventions.
They are especially useful for reproducible preclinical evaluation of anticancer drugs and radiation, as well as controlled studies of tumor progression. Their principal limitation is interpretive: reduced adaptive immune function does not reproduce the immune environment of patients with intact immune systems. Consequently, results can guide research decisions but may not fully predict clinical outcomes.